Journal profile · Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

Current Enzyme Inhibition

ISSN 1573-4080 · eISSN 1875-6662 · Bentham

Current Enzyme Inhibition: subscription journal; median 93 days to acceptance (59 articles, last 24 months); 41 articles in 2025; indexed in Scopus.

Impact factor—No published value
CAS zone—Not in the CAS Journal Ranking
CiteScore quartileQ4Biochemistry · rank 378/448 · 15th percentile
Review time93 daysMedian, submission to acceptance · 59 articles, last 24 months · Crossref
APC—No source gives fee information
Acceptance—No reports yet
Articles per year412025 · OpenAlex count

Scope

Aims, scope and focus

Current Enzyme Inhibition is published by Bentham. By OpenAlex counts of its recent articles, its largest topics are Computational Drug Discovery Methods, Synthesis and biological activity and Natural Antidiabetic Agents Studies, together about 26.4% of its articles. (generated from OpenAlex topic counts and CAS ranking data)

Research area (LetPub): Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

Main research topics OpenAlex counts of recent articles; shares are approximate

  1. Computational Drug Discovery MethodsComputer Science9.6%
  2. Synthesis and biological activityChemistry8.8%
  3. Natural Antidiabetic Agents StudiesMedicine8%
  4. Enzyme function and inhibitionBiochemistry, Genetics and Molecular Biology6.5%
  5. Medicinal Plant ResearchAgricultural and Biological Sciences6.5%
  6. Cholinesterase and Neurodegenerative DiseasesMedicine5.8%
  7. Synthesis and Characterization of Heterocyclic CompoundsChemistry5.7%
  8. Protease and Inhibitor MechanismsBiochemistry, Genetics and Molecular Biology4.6%

Rankings & indexing

CAS ranking and database indexing

CAS Journal Ranking

CAS Journal Ranking, upgraded edition (March 2025)Not covered

Not covered by this edition.

CAS Xinrui Journal Ranking (March 2026)Not covered

Not covered by this edition.

CAS Journal Ranking, previous upgraded edition (December 2023)Not covered

Not covered by this edition.

CiteScore quartiles (Scopus, June 2026 release)

SubjectQuartileRankPercentile
BiochemistryQ4378/44815th
Drug DiscoveryQ4139/16113th
Molecular MedicineQ4160/17910th

Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub

Database indexing

ScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Metrics

Impact metrics and publication volume

Impact

CiteScore 2026-06
1.5LetPub ·
SJR 2026-06
0.24LetPub ·
SNIP 2026-06
0.29LetPub ·
h-index
23OpenAlex ·
i10-index
80OpenAlex ·
2-year mean citedness
0.54OpenAlex ·
Share of gold OA articles
0%LetPub ·

Articles by year OpenAlex count · 556 in total · the current year is incomplete

YearArticlesOpen accessCitations
2026240173
2025410240
2024180215
2023260215
2022330213
2021201186

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Review & acceptance

Review time and acceptance

Review time from article dates manuscript dates registered with Crossref · to

93 daysMedian, submission to acceptance · P25–P75 71 days – 126 days

Acceptance to online
median 243 days (59 articles)
Submission to online
median 367 days
Sample
59 articles with submission and acceptance dates (74 in the window); the latest was accepted on

Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

Fees & open access

APC and open-access policy

Subscription journalLetPub

A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.

No source has fee information yet; check the journal's website.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Profile

Publication details and official links

Publisher
Bentham
ISSN
1573-4080
Electronic ISSN
1875-6662

FAQ

Frequently asked questions about Current Enzyme Inhibition

How long does peer review take at Current Enzyme Inhibition?

Based on the dates recorded on 59 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 93 days (interquartile range 71–126 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.

Which databases index Current Enzyme Inhibition?

According to LetPub and DOAJ records, Current Enzyme Inhibition is indexed in Scopus.

Is Current Enzyme Inhibition open access, and what is the APC?

Current Enzyme Inhibition is a subscription journal. Fee information is not available yet; check the journal's website.

Sources and updates

The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .